Bank of New York Mellon’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.5M | Buy |
1,314,760
+483,330
| +58% | +$3.66M | ﹤0.01% | 1955 |
|
|
2026
Q1 | $6.38M | Sell |
831,430
-50,897
| -6% | -$348K | ﹤0.01% | 2183 |
|
|
2025
Q4 | $1.75M | Buy |
882,327
+123,546
| +16% | +$280K | ﹤0.01% | 2914 |
|
|
2025
Q3 | $1.87M | Buy |
758,781
+24,061
| +3% | +$62K | ﹤0.01% | 2837 |
|
|
2025
Q2 | $1.94M | Buy |
734,720
+232,451
| +46% | +$625K | ﹤0.01% | 2770 |
|
|
2025
Q1 | $1.51M | Buy |
502,269
+2,741
| +0.5% | +$8.31K | ﹤0.01% | 2819 |
|
|
2024
Q4 | $1.28M | Sell |
499,528
-5,793
| -1% | -$24.1K | ﹤0.01% | 3002 |
|
|
2024
Q3 | $1.88M | Sell |
505,321
-116,215
| -19% | -$538K | ﹤0.01% | 2778 |
|
|
2024
Q2 | $3.93M | Buy |
621,536
+170,742
| +38% | +$1.13M | ﹤0.01% | 2455 |
|
|
2024
Q1 | $2.42M | Sell |
450,794
-31,641
| -7% | -$143K | ﹤0.01% | 2666 |
|
|
2023
Q4 | $2.42M | Sell |
482,435
-35,792
| -7% | -$112K | ﹤0.01% | 2730 |
|
|
2023
Q3 | $876K | Sell |
518,227
-3,581
| -0.7% | -$7.19K | ﹤0.01% | 3234 |
|
|
2023
Q2 | $1.45M | Buy |
521,808
+81,475
| +19% | +$230K | ﹤0.01% | 3009 |
|
|
2023
Q1 | $801K | Sell |
440,333
-9,616
| -2% | -$29.9K | ﹤0.01% | 3234 |
|
|
2022
Q4 | $2.28M | Buy |
449,949
+8,451
| +2% | +$46.4K | ﹤0.01% | 2787 |
|
|
2022
Q3 | $2.19M | Buy |
441,498
+83,140
| +23% | +$379K | ﹤0.01% | 2782 |
|
|
2022
Q2 | $1.33M | Buy |
358,358
+15,580
| +5% | +$62.6K | ﹤0.01% | 3058 |
|
|
2022
Q1 | $1.92M | Sell |
342,778
-11,442
| -3% | -$70.2K | ﹤0.01% | 2958 |
|
|
2021
Q4 | $2.15M | Buy |
354,220
+2,640
| +0.8% | +$19.8K | ﹤0.01% | 2950 |
|
|
2021
Q3 | $3.42M | Buy |
351,580
+41,531
| +13% | +$457K | ﹤0.01% | 2689 |
|
|
2021
Q2 | $4.43M | Buy |
310,049
+143,202
| +86% | +$2.37M | ﹤0.01% | 2553 |
|
|
2021
Q1 | $3.96M | Sell |
166,847
-53,330
| -24% | -$1.38M | ﹤0.01% | 2555 |
|
|
2020
Q4 | $2.94M | Buy |
220,177
+42,692
| +24% | +$411K | ﹤0.01% | 2622 |
|
|
2020
Q3 | $1.23M | Sell |
177,485
-3,357
| -2% | -$33.5K | ﹤0.01% | 2994 |
|
|
2020
Q2 | $2.22M | Buy |
180,842
+72,991
| +68% | +$412K | ﹤0.01% | 2623 |
|
|
2020
Q1 | $311K | Sell |
107,851
-1,290
| -1% | -$6.46K | ﹤0.01% | 3583 |
|
|
2019
Q4 | $414K | Sell |
109,141
-1,485
| -1% | -$2.53K | ﹤0.01% | 3684 |
|
|
2019
Q3 | $135K | Buy |
110,626
+31,982
| +41% | +$39.7K | ﹤0.01% | 3978 |
|
|
2019
Q2 | $80K | Sell |
78,644
-81,792
| -51% | -$94.3K | ﹤0.01% | 4062 |
|
|
2019
Q1 | $254K | Buy |
160,436
+59,473
| +59% | +$74.7K | ﹤0.01% | 3799 |
|
|
2018
Q4 | $117K | Sell |
100,963
-48,489
| -32% | -$111K | ﹤0.01% | 3938 |
|
|
2018
Q3 | $553K | Sell |
149,452
-20,819
| -12% | -$65.8K | ﹤0.01% | 3600 |
|
|
2018
Q2 | $521K | Buy |
170,271
+49,040
| +40% | +$182K | ﹤0.01% | 3616 |
|
|
2018
Q1 | $471K | Buy |
121,231
+178
| +0.1% | +$780 | ﹤0.01% | 3616 |
|
|
2017
Q4 | $544K | Buy |
121,053
+3,886
| +3% | +$18.4K | ﹤0.01% | 3584 |
|
|
2017
Q3 | $642K | Sell |
117,167
-5,044
| -4% | -$31.1K | ﹤0.01% | 3463 |
|
|
2017
Q2 | $928K | Buy |
122,211
+39,823
| +48% | +$172K | ﹤0.01% | 3292 |
|
|
2017
Q1 | $292K | Sell |
82,388
-14,225
| -15% | -$70.3K | ﹤0.01% | 3758 |
|
|
2016
Q4 | $553K | Buy |
96,613
+11,146
| +13% | +$74.4K | ﹤0.01% | 3544 |
|
|
2016
Q3 | $666K | Buy |
85,467
+7,024
| +9% | +$52.5K | ﹤0.01% | 3393 |
|
|
2016
Q2 | $487K | Buy |
78,443
+22,155
| +39% | +$172K | ﹤0.01% | 3551 |
|
|
2016
Q1 | $463K | Buy |
56,288
+14,965
| +36% | +$141K | ﹤0.01% | 3475 |
|
|
2015
Q4 | $715K | Buy |
41,323
+23,763
| +135% | +$353K | ﹤0.01% | 3363 |
|
|
2015
Q3 | $201K | Buy |
+17,560
| New | +$383K | ﹤0.01% | 3907 |
|
Other funds holding IBRX
SAM
N
CCA
AH
Bank of New York Mellon's IBRX Position: Q2 2026 in Review
Bank of New York Mellon increased its ImmunityBio (IBRX) stake by 58% in Q2 2026, buying an estimated $3.66M and bringing the position to 1,314,760 shares worth $11.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1955.
Bank of New York Mellon first reported a position in IBRX in Q3 2015 and has held it in 44 quarters since. 239 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.
- Bank of New York Mellon held 1,314,760 shares of ImmunityBio worth $11.5M as of Q2 2026.
- Bank of New York Mellon bought 483,330 ImmunityBio shares in Q2 2026, an estimated $3.66M.
- ImmunityBio made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1955 holding.
- Bank of New York Mellon first reported a position in ImmunityBio in Q3 2015 and has held it in 44 quarters since.
- 239 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.